JP2012533540A5 - - Google Patents

Download PDF

Info

Publication number
JP2012533540A5
JP2012533540A5 JP2012520598A JP2012520598A JP2012533540A5 JP 2012533540 A5 JP2012533540 A5 JP 2012533540A5 JP 2012520598 A JP2012520598 A JP 2012520598A JP 2012520598 A JP2012520598 A JP 2012520598A JP 2012533540 A5 JP2012533540 A5 JP 2012533540A5
Authority
JP
Japan
Prior art keywords
injection
glatiramer acetate
aqueous pharmaceutical
mannitol
outer shell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012520598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012533540A (ja
Filing date
Publication date
Priority claimed from US12/761,367 external-priority patent/US20110060279A1/en
Application filed filed Critical
Publication of JP2012533540A publication Critical patent/JP2012533540A/ja
Publication of JP2012533540A5 publication Critical patent/JP2012533540A5/ja
Pending legal-status Critical Current

Links

JP2012520598A 2009-07-15 2010-07-14 グラチラマーアセテートの減量製剤および投与法 Pending JP2012533540A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US27100909P 2009-07-15 2009-07-15
US61/271,009 2009-07-15
US27134009P 2009-07-20 2009-07-20
US61/271,340 2009-07-20
US33701110P 2010-01-29 2010-01-29
US61/337,011 2010-01-29
US12/761,367 US20110060279A1 (en) 2009-07-15 2010-04-15 Reduced Volume Formulation of Glatiramer Acetate and Methods of Administration
US12/761,367 2010-04-15
PCT/US2010/001972 WO2011008274A2 (en) 2009-07-15 2010-07-14 Reduced volume formulation of glatiramer acetate and methods of administration

Publications (2)

Publication Number Publication Date
JP2012533540A JP2012533540A (ja) 2012-12-27
JP2012533540A5 true JP2012533540A5 (https=) 2013-09-05

Family

ID=42283140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012520598A Pending JP2012533540A (ja) 2009-07-15 2010-07-14 グラチラマーアセテートの減量製剤および投与法

Country Status (19)

Country Link
US (3) US20110060279A1 (https=)
EP (2) EP2275086B1 (https=)
JP (1) JP2012533540A (https=)
AR (1) AR077484A1 (https=)
AT (1) ATE549013T1 (https=)
AU (1) AU2010273234A1 (https=)
BR (1) BR112012000878A2 (https=)
CA (1) CA2697570C (https=)
DK (1) DK2275086T3 (https=)
EA (1) EA201270167A1 (https=)
ES (1) ES2383347T3 (https=)
HR (1) HRP20120349T1 (https=)
IL (1) IL217240A0 (https=)
MX (1) MX2012000687A (https=)
PL (1) PL2275086T3 (https=)
PT (1) PT2275086E (https=)
RS (1) RS52367B (https=)
WO (1) WO2011008274A2 (https=)
ZA (1) ZA201200586B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US12097357B2 (en) 2008-09-15 2024-09-24 West Pharma. Services IL, Ltd. Stabilized pen injector
CA2697570C (en) * 2009-07-15 2011-11-01 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
NZ598661A (en) 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
CA2814500A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
CN104684603B (zh) * 2012-08-20 2017-11-24 卡贝欧洲有限公司 自动注射装置
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
WO2014128079A1 (en) * 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
PE20151577A1 (es) * 2013-03-08 2015-11-19 Teva Pharma Dispositivo inyector reutilizable para jeringa
US8591463B1 (en) 2013-03-08 2013-11-26 Teva Pharmaceutical Industries Ltd. Re-useable injector device for syringe
BR112015021548A2 (pt) * 2013-03-08 2017-07-18 Teva Pharmaceutical Industries Ltd dispositivo injetor reutilizável para seringa
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
EP3110375B1 (en) 2014-02-26 2022-01-26 Allergan, Inc. Intraocular implant delivery apparatus
US9415176B1 (en) 2015-01-22 2016-08-16 West Pharmaceutical Services, Inc. Autoinjector having an end-of-dose visual indicator
US9155775B1 (en) * 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
EP3534893A1 (en) * 2016-11-02 2019-09-11 To Pharmaceuticals LLC Combination therapy of cbd and copaxone
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
US20200306516A1 (en) 2017-08-14 2020-10-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2017924B3 (es) * 1985-10-11 1991-03-16 Duphar Int Res B V Inyector automatico.
NL8701091A (nl) * 1987-05-08 1988-12-01 Spruyt Hillen Bv Injectiepen.
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
GB8926825D0 (en) * 1989-11-28 1990-01-17 Glaxo Group Ltd Device
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6454746B1 (en) * 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
SE518981C2 (sv) 2000-12-14 2002-12-17 Shl Medical Ab Autoinjektor
AU2003275895B2 (en) * 2002-11-25 2009-02-05 Tecpharma Licensing Ag Auto-injector comprising a resettable releasing safety device
JP2007507541A (ja) * 2003-10-03 2007-03-29 ベイヒル セラピューティクス インコーポレーティッド 修飾型の規則正しいペプチドによる脱髄性自己免疫性疾患の治療方法
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
EP1796710A4 (en) * 2004-09-02 2010-05-26 Teva Pharma THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
AR052321A1 (es) * 2004-10-29 2007-03-14 Sandoz Ag Procesos para la preparacion de un polipeptido
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20070161960A1 (en) * 2006-01-12 2007-07-12 Fu-Yuan Li Lancet device
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
MX2008016335A (es) * 2006-06-30 2009-01-21 Abbott Biotech Ltd Dispositivo automatico de inyeccion.
USD622374S1 (en) * 2006-09-06 2010-08-24 Abbott Biotechnology Ltd. Automatic injection device
CA2702437C (en) * 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Method of delaying the onset of clinically definite multiple sclerosis
USD607558S1 (en) * 2008-09-19 2010-01-05 Becton Dickinson France S.A.S. Medicine injector
CA2697570C (en) 2009-07-15 2011-11-01 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration

Similar Documents

Publication Publication Date Title
JP2012533540A5 (https=)
WO2011008274A4 (en) Reduced volume formulation of glatiramer acetate and methods of administration
TWI477273B (zh) 低頻率格拉替雷(glatiramer)醋酸鹽之治療
JP2005501110A5 (https=)
TWI580422B (zh) Compositions for reducing local fat and weight loss, and pharmaceuticals and applications thereof
JP2020514305A5 (https=)
KR20180100309A (ko) 데옥시콜산 및 이의 염을 사용한 축적된 지방의 치료 방법
Shvartsman et al. Therapy of moderate cognitive impairment and asthenia in patients with cerebrovascular pathology: results of a prospective observational study
CN111214469B (zh) 预防和治疗慢性疼痛的化合物及其应用
Neville et al. Treatment of severe cutaneous ulcerative lichen planus with low molecular weight heparin in a patient with hepatitis C
Lewis et al. The use of high-dose lidocaine in wetting solutions for lipoplasty
WO2014190063A1 (en) Methods for the treatment of premature ejaculation
Lee et al. Suspected anaphylactic reaction associated with microemulsion propofol during anesthesia induction
Kim et al. Scleredema adultorum of Buschke treated by extracorporeal shock wave therapy.
Joly et al. 639 Design of marigold-bp: A phase 2/3 study of nipocalimab in adults with moderate to severe bullous pemphigoid
Iqneibi et al. 636 Successful treatment of pachyonychia congenita with simvastatin
Verma et al. Nicolau syndrome postintramuscular diclofenac injection: preventable iatrogenic error or an unfortunate sequalae?
Yildiz et al. A case of Nicolau syndrome treated with hyperbaric oxygen
CN117860866A (zh) 用于女性性功能障碍的布雷默浪丹疗法
RU2858232C1 (ru) Безоперационный способ лечения болезни пейрони
RU2286162C1 (ru) Способ лечения кожных проявлений склеродермии
US20180311194A1 (en) Application of tranilast in preparation of drug treating scleredema diabeticorum
Zhang et al. 637 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: Onset of action and maintenance of response in the phase 3 POETYK PSO-3 trial
Nobari et al. 640 Treatment of recalcitrant cutaneous warts with intralesional injection of HBV vaccine
AU2016100455B4 (en) Low frequency glatiramer acetate therapy